# Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma

> **NCT01242930** · PHASE2 · COMPLETED · sponsor: **Geron Corporation** · enrollment: 13 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Imetelstat (7.5 mg/kg)
- **DRUG:** lenalidomide standard of care
- **DRUG:** Imetelstat (9.4 mg/kg)

## Key facts

- **NCT ID:** NCT01242930
- **Lead sponsor:** Geron Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2016-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01242930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01242930, "Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01242930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*